



Characterization of the novel HLA-C*05:01:01:81Q allele by sequencing-based typing

Marine Cargou, Vincent Elsermans, Virginie Raclet, Elodie Wojciechowski,
Jonathan Visentin

► To cite this version:

Marine Cargou, Vincent Elsermans, Virginie Raclet, Elodie Wojciechowski, Jonathan Visentin. Characterization of the novel HLA-C*05:01:01:81Q allele by sequencing-based typing. *HLA: Immune Response Genetics*, 2023, 102 (1), pp.93-95. <10.1111/tan.15009>. <hal-04623294>

HAL Id: hal-04623294

<https://hal.science/hal-04623294v1>

Submitted on 25 Jun 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC-ND 4.0 - Attribution - Non-commercial use - No
Derivative Works - International License

⁴Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France

Correspondence

Marine Cargou, CHU de Bordeaux,
Laboratoire d'Immunologie et
Immunogénétique, Hôpital Pellegrin,
Place Amélie Raba Léon, 33076 Bordeaux
Cedex, France.
Email: marine.cargou@chu-bordeaux.fr

*HLA-C*05:01:01:81Q* differs from *HLA-C*05:01:01:02* by one nucleotide substitution in position 202 in intron 1 (c.74-2A>G, hg19).

KEYWORDS

HLA, *HLA-C*05:01:01:81Q*, novel allele, sequencing-based typing

We report here a novel *HLA-C*05* allele, now named *HLA-C*05:01:01:81Q* that carries one nucleotide substitution in acceptor splice site of intron 1 (c.74-2A>G) when compared with the *HLA-C*05:01:01:02* allele, identified in a volunteer bone marrow donor. The genomic coordinates (GRCh37) of the variant are Chr6(GRCh37):g.31239647T>C. The HLA typing was performed using Next Generation Sequencing (AllType NGS, One Lambda, Canoga Park, CA) on the Ion S5 system platform (ThermoFisher Scientific, Waltham, MA),¹ from exons 1 to 8. The reads were analyzed using the TypeStream Visual Software version 2.1 (One Lambda). This patient was found to have a new *C*05* allele and was consequently typed *A*02:01*, *29:02*; *B*40:01*, *57:01*; *C*05:01:01:81Q*, *16:01:01:01*; *DRB1*07:01*, *07:01*; *DRB4*01:01*, *01:03:01:02N*; *DQA1*02:01*, *02:01*; *DQB1*02:02*, *03:03*; *DPA1*02:01*, *02:02*; *DPB1*01:01*, *11:01*. Using the IPD-IMGT/HLA Database,² nucleotide sequence alignment with HLA-C alleles shows that this new allele has one nucleotide change from *C*05:01:01:02* in acceptor splice site of intron 1 (c.74-2A>G) (Figure 1). Three softwares predicted a change at acceptor site 2 bps downstream (MaxEnt, NNSPLICE and SSF) with a score of 1 and SpliceAI software with a score of 0.57, resulting in a high probability of abolition of the splice site. This nucleotide change was confirmed using other NGS reagents provided by Immucor

(Mia Fora NGS Flex, Norcross, GA) run on the Illumina MiSeq system (San Diego, CA) and analyzed with the Mia Fora Flex software (version 5.1). We were very confident in the phasing as the sample displayed a mean read length of 304 base pairs over all the loci, the mismatched G base was attributed 229 times to the new *HLA-C*05* allele and can be only attributed to this allele because it was possible to discriminate from the associated *HLA-C*16:01:01:01* allele by virtue of 2 variant positions each distant by less than 100 base pairs. *C*05:01:01:81Q* was not evaluated easily with T or B cell flow cytometry crossmatch (FCXM).^{3,4} Furthermore none LCT Typing kit is available to demonstrate the lack of expression of this antigen. Despite these drawbacks, it is highly probable that the abolition of the splice site leads to a frameshift variant and a truncated protein. As such this could have an importance in both allogeneic hematopoietic stem cell transplantation and solid organ transplantation. The coding nucleotide sequence of the new allele has been submitted to the GenBank database (Accession No. OM913145) and to the IPD-IMGT/HLA Database (Submission No. HWS10060752). The name *C*05:01:01:81Q* has been officially assigned by the WHO Nomenclature Committee for Factors of the HLA System in March 2022. This follows the agreed policy that, subject to the conditions




FIGURE 1 Alignment of the sequence of exon 1, intron 1, exon 2 and partial intron 2 of *HLA-C*05:01:01:81Q* with the sequence of *HLA-C*05:01:01:02*. Dashes indicate nucleotide identity with the *HLA-C*05:01:01:02* allele. Numbers above the sequence indicate nucleotide position. Pipes (|) are used to indicate the exon, intron boundary.

stated in the most recent Nomenclature Report,⁵ names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report.

AUTHOR CONTRIBUTIONS

Marine Cargou and Jonathan Visentin contributed to the design of the study. Marine Cargou and Jonathan Visentin participated in the writing of the paper. Marine Cargou, Vincent Elsermans, Virginie Raclet, Elodie Wojciechowski, and Jonathan Visentin participated in the performance of the research. Marine Cargou, Vincent Elsermans, Virginie Raclet, Elodie Wojciechowski, and Jonathan Visentin participated in data analysis. Vincent Elsermans, Virginie Raclet, and Elodie Wojciechowski were involved in critical revision of the manuscript.

ACKNOWLEDGMENTS

The authors thank the technicians of the Bordeaux and Lille Immunology laboratory and the laboratory of Genetics at Bordeaux University Hospital for their technical expertise.

CONFLICT OF INTEREST STATEMENT


The authors confirm that there are no conflicts of interest.


DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. The sequence is freely available in the IPD-IMGT/HLA Database.

ORCID

Marine Cargou  <https://orcid.org/0000-0002-1141-1417>

Vincent Elsermans  <https://orcid.org/0000-0002-0881-0695>

Jonathan Visentin  <https://orcid.org/0000-0003-3795-8979>

REFERENCES

1. Cargou M, Ralazamahaleo M, Blouin L, et al. Evaluation of the AllType kit for HLA typing using the ion torrent S5 XL platform. *HLA*. 2020;95(1):30-39. doi:[10.1111/tan.13708](https://doi.org/10.1111/tan.13708)
2. Barker DJ, Maccari G, Georgiou X, et al. The IPD-IMGT/HLA database. *Nucleic Acids Res*. 2023;51(D1):D1053-D1060. doi:[10.1093/nar/gkac1011](https://doi.org/10.1093/nar/gkac1011)
3. Visentin J, Couzi L, Taupin J. Clinical relevance of donor-specific antibodies directed at HLA-C: a long road to acceptance. *HLA*. 2021;97(1):3-14. doi:[10.1111/tan.14106](https://doi.org/10.1111/tan.14106)
4. Visentin J, Bachelet T, Aubert O, et al. Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. *Am J Transplant*. 2020;20(5):1365-1374. doi:[10.1111/ajt.15766](https://doi.org/10.1111/ajt.15766)
5. Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. *Tissue Antigens*. 2010;75(4):291-455. doi:[10.1111/j.1399-0039.2010.01466.x](https://doi.org/10.1111/j.1399-0039.2010.01466.x)

How to cite this article: Cargou M, Elsermans V, Raclet V, Wojciechowski E, Visentin J. Characterization of the novel *HLA-C*05:01:01:81Q* allele by sequencing-based typing. *HLA*. 2023; 102(1):93-95. doi:[10.1111/tan.15009](https://doi.org/10.1111/tan.15009)

A novel *HLA-C*06* allele, *HLA-C*06:02:96*, identified by next-generation sequencing in a Chinese family

Xiaojing Wang  | Jiying Wang | Yan Zhang | Yao Yao

Department of Pathology and Lab Medicine, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Correspondence

Xiaojing Wang, Department of Pathology and Lab Medicine, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese

*HLA-C*06:02:96* differs from *HLA-C*06:02:01:01* (924C → A, I284I), resulting in a synonymous change in exon 5.

KEYWORDS

HLA, new allele, next-generation sequencing